Oric Pharmaceuticals Inc. announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. The results, which have already been presented, included findings in previously treated non-small cell lung cancer (NSCLC) patients with EGFR atypical mutations and preliminary data in first-line NSCLC patients with EGFR P-loop and alpha C-helix compressing (PACC) mutations. The study reported an 80% overall response rate $(ORR)$ and 100% intracranial ORR in first-line EGFR PACC patients, as well as a 36% ORR in later-line EGFR PACC patients. Enozertinib was reported to have a competitive safety profile with manageable toxicity and a low discontinuation rate. Further enrollment and follow-up in first-line EGFR PACC patients are ongoing at a selected dose, with the next data update expected in mid-2026 ahead of a potential Phase 3 trial.